Illumina, Inc. (ILMN)

US — Healthcare Sector
Peers: DGX  WAT  MEDP  ZBH  HOLX  THC  ICLR  WST  GMAB  LH 

Automate Your Wheel Strategy on ILMN

With Tiblio's Option Bot, you can configure your own wheel strategy including ILMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ILMN
  • Rev/Share 27.4808
  • Book/Share 15.2628
  • PB 8.4336
  • Debt/Equity 1.0819
  • CurrentRatio 1.4251
  • ROIC 0.1203

 

  • MktCap 19668416000.0
  • FreeCF/Share 6.4103
  • PFCF 19.6684
  • PE 28.5638
  • Debt/Assets 0.417
  • DivYield 0
  • ROE 0.2998

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 3
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ILMN Daiwa Securities Outperform Neutral -- $94 Aug. 12, 2025
Downgrade ILMN Scotiabank Sector Outperform Sector Perform -- $125 July 11, 2025
Reiterated ILMN Citigroup -- Neutral $130 $90 March 4, 2025
Downgrade ILMN HSBC Securities Buy Hold -- $100 Feb. 28, 2025
Downgrade ILMN Barclays Equal Weight Underweight $130 $100 Feb. 10, 2025
Downgrade ILMN TD Cowen Buy Hold $177 $140 Feb. 7, 2025
Downgrade ILMN Citigroup Buy Neutral $190 $165 Dec. 11, 2024
Upgrade ILMN HSBC Securities Hold Buy -- $180 Oct. 17, 2024
Upgrade ILMN Argus Hold Buy -- -- Aug. 28, 2024
Upgrade ILMN Daiwa Securities Neutral Buy $120 $154 Aug. 16, 2024

News

ILMN vs. ALNY: Which Stock Is the Better Value Option?
ALNY, ILMN
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news ILMN vs. ALNY: Which Stock Is the Better Value Option?
Why Illumina Stock Got Mashed on Monday
ILMN
Published: February 10, 2025 by: The Motley Fool
Sentiment: Negative

On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.

Read More
image for news Why Illumina Stock Got Mashed on Monday

About Illumina, Inc. (ILMN)

  • IPO Date 2000-07-28
  • Website https://www.illumina.com
  • Industry Medical - Diagnostics & Research
  • CEO Jacob Thaysen
  • Employees 8970

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.